Detalhe da pesquisa
1.
The gut-liver axis in cholangiopathies: focus on bile acid based pharmacological treatment.
Curr Opin Gastroenterol
; 38(2): 136-143, 2022 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35034082
2.
Proteomics and Lipidomics in Inflammatory Bowel Disease Research: From Mechanistic Insights to Biomarker Identification.
Int J Mol Sci
; 19(9)2018 Sep 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-30223557
3.
Activation of bile salt nuclear receptor FXR is repressed by pro-inflammatory cytokines activating NF-κB signaling in the intestine.
Biochim Biophys Acta
; 1812(8): 851-8, 2011 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-21540105
4.
Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease.
Gut
; 60(4): 463-72, 2011 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-21242261
5.
Bile acids and their nuclear receptor FXR: Relevance for hepatobiliary and gastrointestinal disease.
Biochim Biophys Acta
; 1801(7): 683-92, 2010 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-20399894
6.
Pharmacological activation of the bile acid nuclear farnesoid X receptor is feasible in patients with quiescent Crohn's colitis.
PLoS One
; 7(11): e49706, 2012.
Artigo
em Inglês
| MEDLINE | ID: mdl-23189156
7.
Farnesoid X receptor (FXR) activation and FXR genetic variation in inflammatory bowel disease.
PLoS One
; 6(8): e23745, 2011.
Artigo
em Inglês
| MEDLINE | ID: mdl-21887309
8.
Deciphering the nuclear bile acid receptor FXR paradigm.
Nucl Recept Signal
; 8: e005, 2010 Nov 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-21383957